NCT02235272View on ClinicalTrials.gov

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

PHASE3CompletedINTERVENTIONAL
Enrollment

339

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
InflammationPainCataract
Interventions
DRUG

XG-102

Comparison of XG-102 versus placebo sub-conjunctival injection efficacy

DRUG

Placebo

comparison of XG-102 versus placebo sub-conjunctival injection efficacy

Trial Locations (1)

92843

Garden Grove

All Listed Sponsors
lead

Xigen SA

INDUSTRY

NCT02235272 - Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation | Biotech Hunter | Biotech Hunter